Clinical Trial News and Research

RSS

ARCA biopharma extends pharmacogenetic intellectual property protection around bucindolol

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Patent and Trademark Office has issued a patent on methods for treating patients with bucindolol based on genetic targeting and focused on a specific genotype - homozygous wildtype for Deletion 322-325 in the alpha-2C adrenergic receptor.

31 Dec 2011

Avastin fails to live up to expectations for extending survival in ovarian cancer

Cancer drug Avastin has been found to add about four months to the time it takes for the cancer to worsen for women with advanced cases of ovarian cancer says a new report. However it may not extend survival significantly.

29 Dec 2011

GOG targeted therapy phase 3 clinical trial delays progression of advanced ovarian cancer

Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer.

29 Dec 2011

Bevacizumab delays disease progression in ovarian cancer

Treating ovarian cancer with the drug bevacizumab ("Avastin") delays the disease and may also improve survival, show the results of an international clinical trial co-led by Drs. Amit Oza of the Princess Margaret Cancer Program, University Health Network and Timothy Perren, St James's Institute of Oncology, Leeds, UK.

29 Dec 2011

Emergent commences Phase 2 combination trial of TRUw-016 with bendamustine in relapsed CLL

Emergent BioSolutions Inc. today announced the initiation of a Phase 2 study (protocol 16201) of TRU-016 in combination with bendamustine for patients with relapsed chronic lymphocytic leukemia (CLL).

29 Dec 2011

Critical considerations for adenovirus-based HIV vaccine trials

A clinical trial testing a candidate HIV vaccine known as the STEP study was halted in September 2007 after interim analysis indicated that the vaccine did not work. Moreover, subsequent analyses indicated that the vaccine made some individuals more susceptible to HIV, in particular individuals who had pre-existing immune effectors (antibodies) that recognized a component of the vaccine (adenovirus serotype 5 [Ad5]).

28 Dec 2011

IL-1 gene inactivation may reduce severe clinical complications of atherosclerosis

Atherosclerosis is a disease of the major arterial blood vessels. It is one of the major causes of heart attack and stroke. The proinflammatory molecule IL-1 has been linked to atherosclerosis and a clinical trial has been launched in which an antibody specific for IL-1-beta is being studied for its effects on the severe clinical complications of atherosclerosis.

28 Dec 2011

Transparency needed in clinical trial recruitment performance

Despite the importance of site investigators to the success of multicentre clinical trials, inadequate public information is available about their recruitment performance. In this week's PLoS Medicine, Rafael Dal-R- and colleagues argue that that sponsors should disclose the recruitment targets of all site investigators on ClinicalTrials.gov before a trial starts, as well as their final recruitment.

28 Dec 2011

CEL-SCI to expand Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation is in the process of expanding its Phase III clinical trial of the investigational therapy Multikine (Leukocyte Interleukin, Injection) to 4 additional European countries - Spain, Czech Republic, Slovakia and Croatia.

27 Dec 2011

Initial results from 22nd Century's X-22 Phase II-B smoking cessation trial

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced X-22, a prescription smoking cessation aid in development consisting of very low nicotine (VLN) cigarettes, showed a reduction of smoking from baseline over the 6-week treatment period in the company's Phase II-B clinical trial.

26 Dec 2011

CEL-SCI reports net loss of $26.8M for fiscal year ended September 30, 2011

CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2011.

26 Dec 2011

MindFrame establishes ischemic stroke Registry

MindFrame Inc. today announces the establishment of an ischemic stroke Registry that will collect real-world clinical and procedural data through a secure web-based portal accessible only to registered clinician members.

23 Dec 2011

Science names HIV prevention trial as '2011 Breakthrough of the Year'

"The journal Science has chosen the HPTN 052 clinical trial, an international HIV prevention trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID)," which found that early treatment with antiretroviral drugs (ARVs) reduced the risk of transmission among sero-discordant partners by 96 percent, as the "2011 Breakthrough of the Year," an NIH press release states (12/22).

23 Dec 2011

ARV drugs can prevent transmission of HIV

The finding of a team of researchers - including several members from Johns Hopkins - that HIV treatment with antiretroviral drugs (ARVs) can actually prevent transmission of the virus from an infected person to his or her uninfected partner has been named "Breakthrough of the Year" for 2011 by the journal Science.

23 Dec 2011

MSF publishes list of top 10 stories of 2011 about access to medicine

This Medecins Sans Frontieres (MSF) special report highlights the top 10 stories of 2011 regarding access to essential medicines, according to MSF.

23 Dec 2011

Researchers discover key interaction at heart of promising new treatment for Fabry disease

A research team led by biochemist Scott Garman at the University of Massachusetts Amherst has discovered a key interaction at the heart of a promising new treatment for a rare childhood metabolic disorder known as Fabry disease.

23 Dec 2011

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

Researchers from the John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, presented results from 31 major studies of blood-related cancers - leukemia, lymphoma and multiple myeloma -- during the American Society of Hematology (ASH) Annual Meeting, December 10-13, 2011 in San Diego.

23 Dec 2011

Scientists discover mechanism by which TNFα stimulates tumor formation

An inflammation-promoting protein triggers deactivation of a tumor-suppressor that usually blocks cancer formation via the NOTCH signaling pathway, a team of researchers led by scientists at The University of Texas MD Anderson Cancer Center reports today in Molecular Cell.

23 Dec 2011

Abbott commences Esprit drug eluting BVS trial in peripheral artery disease

Abbott today announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit drug eluting bioresorbable vascular scaffold (BVS) for the treatment of blockages in the superficial femoral arteries (SFA) and iliac arteries that have resulted in claudication.

23 Dec 2011

ViroPharma to acquire Meritage

ViroPharma Incorporated today announced that it has entered into an exclusive option to acquire Meritage Pharma, Inc., a private company based in San Diego, CA focused on developing oral budesonide suspension (OBS) as a treatment for eosinophilic esophagitis (EoE), a chronic inflammatory disorder of the esophagus.

23 Dec 2011

Clinical Trial News and Research

ARCA biopharma extends pharmacogenetic intellectual property protection around bucindolol

Avastin fails to live up to expectations for extending survival in ovarian cancer

GOG targeted therapy phase 3 clinical trial delays progression of advanced ovarian cancer

Bevacizumab delays disease progression in ovarian cancer

Emergent commences Phase 2 combination trial of TRUw-016 with bendamustine in relapsed CLL

Critical considerations for adenovirus-based HIV vaccine trials

IL-1 gene inactivation may reduce severe clinical complications of atherosclerosis

Transparency needed in clinical trial recruitment performance

CEL-SCI to expand Multikine Phase III trial in head and neck cancer

Initial results from 22nd Century's X-22 Phase II-B smoking cessation trial

CEL-SCI reports net loss of $26.8M for fiscal year ended September 30, 2011

MindFrame establishes ischemic stroke Registry

Science names HIV prevention trial as '2011 Breakthrough of the Year'

ARV drugs can prevent transmission of HIV

MSF publishes list of top 10 stories of 2011 about access to medicine

Researchers discover key interaction at heart of promising new treatment for Fabry disease

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

Scientists discover mechanism by which TNFα stimulates tumor formation

Abbott commences Esprit drug eluting BVS trial in peripheral artery disease

ViroPharma to acquire Meritage

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer